PFE Beats Q2, Axes Two Obesity Drugs, Backs Berobenatide

Pfizer (PFE) beat Q2 2026 expectations on August 4, reporting EPS of $0.77 versus the $0.68 consensus and revenue of $15.03 billion versus the $14.41 billion estimate. The company raised the midpoint of its full-year revenue guidance by $500 million. But the headline number was not the story. Pfizer axed two clinical-stage obesity programs from the $10 billion Metsera acquisition, narrowing its obesity bet to a single injectable candidate. Shares closed at $25.41.

The numbers

• Ticker: PFE
• Stock price: $25.41 (close August 4)
• Q2 revenue: $15.03 billion (beat $14.41B consensus)
• Q2 EPS: $0.77 (beat $0.68 consensus)
• 2026 revenue guidance: Raised midpoint by $500M
• Paxlovid: -95% YoY
• Comirnaty: -34% YoY

Obesity pipeline: from portfolio to single asset

Pfizer spent roughly $10 billion to acquire Metsera in early 2026, gaining a portfolio that included berobenatide (injectable GLP-1, monthly dosing), MET-224o (oral GLP-1), and PF-07976016 (GIPR antagonist). This quarter, the company discontinued both the oral GLP-1 and the GIPR antagonist, leaving berobenatide as the sole surviving clinical-stage obesity asset from the acquisition. One additional oral candidate, PF-08642534 licensed from YaoPharma, remains in early development.

CSO Chris Boshoff claimed on the earnings call that berobenatide “can deliver weight loss comparable to tirzepatide.” The Phase 2b VESPER-3 data showed 12.3% placebo-adjusted weight loss at 28 weeks, with patients continuing to lose weight after transitioning from weekly to monthly dosing. Pfizer plans 10 Phase 3 studies for berobenatide in 2026, targeting chronic weight management, knee osteoarthritis, and obstructive sleep apnea. The first potential approval is not expected until 2028. For context, the obesity pipeline cut at Roche followed a similar pattern, prune the portfolio, bet on a single lead asset.

COVID unwind masks the underlying business

The revenue beat came despite a near-total COVID unwind. Paxlovid sales collapsed 95% year over year, and Comirnaty fell 34%. Excluding COVID products, Pfizer’s core business showed steady growth driven by oncology (Lorbrena, Talzenna, Xtandi), the Vyndaqel transthyretin amyloidosis franchise, and Eliquis. The TALZENNA plus XTANDI prostate cancer combination added a priority review catalyst during the quarter.

What to watch

Pfizer’s obesity thesis now hinges entirely on berobenatide’s Phase 3 program. The asset faces established competitors: tirzepatide and semaglutide are each generating billions in annual revenue, and a dozen next-generation incretin candidates from Lilly, Novo, Amgen, and Viking are in late-stage development. If berobenatide’s monthly dosing convenience and tolerability profile do not clearly differentiate in Phase 3, Pfizer’s $10 billion obesity bet looks thin. The first Phase 3 readouts, expected in 2027, will determine whether Pfizer has a contender or an also-ran.

What It Means for the Trade

Strip the accounting noise and Q2 was a decent quarter from a core business that is quietly compounding: oncology (Lorbrena, Talzenna, Xtandi), the Vyndaqel franchise, and Eliquis more than absorbed a 95% Paxlovid collapse and a 34% Comirnaty decline. The $500 million guidance raise is real operating momentum. But none of that is why anyone is positioning in PFE. At $25.41, this is a yield-and-catalyst stock, and the only catalyst big enough to matter is berobenatide.

The pipeline cut is the honest part of the print. Pfizer paid roughly $10 billion for a three-asset Metsera portfolio and has now written off two of the three — the oral GLP-1 and the GIPR antagonist — inside six months. Concentrating on berobenatide is rational capital allocation, but it converts a diversified $10 billion bet into a single-asset $10 billion bet with 2028 as the earliest approval. That is worse risk math, not better.

Trial Context

The claim to scrutinize is Boshoff’s “weight loss comparable to tirzepatide.” VESPER-3 showed 12.3% placebo-adjusted weight loss at 28 weeks — a mid-stage number that sits below tirzepatide’s established profile at comparable timepoints, and cross-trial comparisons at different durations and populations are unreliable by definition. What berobenatide genuinely has going for it is the monthly maintenance dosing, which no marketed incretin offers, and continued weight loss after the weekly-to-monthly transition. Ten planned Phase 3 studies across chronic weight management, knee osteoarthritis, and obstructive sleep apnea is a broad bet that monthly dosing wins on convenience and adherence in a market where Lilly and Novo are already generating billions. If the monthly arm cannot hold its weight loss at scale, the differentiation evaporates and Pfizer is marketing a follower product into entrenched formulary positions.

Risks and What Could Go Wrong

1. Phase 3 efficacy compresses. 12.3% placebo-adjusted at 28 weeks leaves little cushion; any plateau after the transition to monthly dosing would gut the convenience thesis.
2. Tolerability. Monthly injectables concentrate dose; nausea and GI discontinuation rates that look acceptable in Phase 2 can worsen at scale.
3. Timing. First approval not until 2028, readouts in 2027 — a decade-class market will have moved on to next-generation entrants from Lilly, Novo, Amgen, and Viking. Pfizer needs the market to stay big enough to share, not to be first.

Pfizer Q2 2026 press release | Pfizer obesity pipeline cleanout (FierceBiotech)